These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38394986)

  • 21. Retinal functional changes measured by frequency-doubling technology in patients treated with hydroxychloroquine.
    Tanga L; Centofanti M; Oddone F; Parravano M; Parisi V; Ziccardi L; Kroegler B; Perricone R; Manni G
    Graefes Arch Clin Exp Ophthalmol; 2011 May; 249(5):715-21. PubMed ID: 21253758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus.
    Martín-Iglesias D; Artaraz J; Fonollosa A; Ugarte A; Arteagabeitia A; Ruiz-Irastorza G
    Lupus; 2019 Apr; 28(4):555-559. PubMed ID: 30755141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort.
    Spinelli FR; Moscarelli E; Ceccarelli F; Miranda F; Perricone C; Truglia S; Garufi C; Massaro L; Morello F; Alessandri C; Valesini G; Conti F
    Lupus; 2018 Sep; 27(10):1616-1623. PubMed ID: 29954281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chloroquine and hydroxychloroquine retinopathy-related risk factors in a Turkish cohort.
    Yaylali SA; Sadigov F; Erbil H; Ekinci A; Akcakaya AA
    Int Ophthalmol; 2013 Dec; 33(6):627-34. PubMed ID: 23456514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
    Goldman A; Bomze D; Dankner R; Hod H; Meirson T; Boursi B; Maor E
    Br J Clin Pharmacol; 2021 Mar; 87(3):1432-1442. PubMed ID: 32964535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Current view on chloroquine derivative treatment from rheumatologist perspective and possible ocular side effects].
    Pawlak-Buś K; Gaca-Wysocka M; Grzybowski A; Leszczyński P
    Pol Merkur Lekarski; 2016 Mar; 40(237):202-6. PubMed ID: 27088206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity.
    Martínez-Costa L; Victoria Ibañez M; Murcia-Bello C; Epifanio I; Verdejo-Gimeno C; Beltrán-Catalán E; Marco-Ventura P
    Can J Ophthalmol; 2013 Oct; 48(5):400-5. PubMed ID: 24093187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population.
    Jorge A; McCormick N; Lu N; Zheng Y; Esdaile J; De Vera M; Choi H; Aviña-Zubieta JA
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1219-1223. PubMed ID: 32407570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence.
    Osmani Z; Schrama TJ; Zacouris-Verweij W; Andersen J; Frankel S; Bultink IEM; Cornet A; van Vollenhoven RF
    Lupus Sci Med; 2021 Mar; 8(1):. PubMed ID: 33795484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nationwide patterns of hydroxychloroquine dosing and monitoring of retinal toxicity in patients with systemic lupus erythematosus.
    Lee JE; Nam DR; Sung YK; Kim YJ; Jung SY
    Sci Rep; 2023 May; 13(1):7270. PubMed ID: 37142639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of hydroxychloroquine retinopathy with long-term use in a cohort of Indian patients with rheumatic diseases.
    Manoj M; Sahoo RR; Singh A; Hazarika K; Bafna P; Kaur A; Wakhlu A
    Rheumatol Int; 2021 May; 41(5):929-937. PubMed ID: 33704526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxychloroquine retinopathy.
    Yusuf IH; Sharma S; Luqmani R; Downes SM
    Eye (Lond); 2017 Jun; 31(6):828-845. PubMed ID: 28282061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis.
    Liu D; Li X; Zhang Y; Kwong JS; Li L; Zhang Y; Xu C; Li Q; Sun X; Tian H; Li S
    Drug Des Devel Ther; 2018; 12():1685-1695. PubMed ID: 29928112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Variability of chloroquine and hydroxychloroquine retinopathy among various ethnicities].
    Giocanti-Aurégan A; Couturier A; Girmens JF; Le Mer Y; Massamba N; Barreau E; Audo I;
    J Fr Ophtalmol; 2018 Apr; 41(4):363-367. PubMed ID: 29678344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.
    Fairley JL; Nikpour M; Mack HG; Brosnan M; Saracino AM; Pellegrini M; Wicks IP
    Intern Med J; 2023 Mar; 53(3):311-317. PubMed ID: 35969110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update.
    Abdulaziz N; Shah AR; McCune WJ
    Curr Opin Rheumatol; 2018 May; 30(3):249-255. PubMed ID: 29517495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Chloroquine retinopathy].
    Nguyen AL; Tan AN; Lavrijsen APM
    Ned Tijdschr Geneeskd; 2018 Dec; 163():. PubMed ID: 30570930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxychloroquine: a multifaceted treatment in lupus.
    Costedoat-Chalumeau N; Dunogué B; Morel N; Le Guern V; Guettrot-Imbert G
    Presse Med; 2014 Jun; 43(6 Pt 2):e167-80. PubMed ID: 24855048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
    Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
    J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity.
    Desmarais J; Rosenbaum JT; Costenbader KH; Ginzler EM; Fett N; Goodman S; O'Dell J; Pineau CA; Schmajuk G; Werth VP; Link MS; Kovacs R
    Arthritis Rheumatol; 2021 Dec; 73(12):2151-2160. PubMed ID: 34697918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.